www.fdanews.com/articles/69471-allos-nabs-50-million-from-warburg-pincus
Allos Nabs $50 Million From Warburg Pincus
March 4, 2005
Publicly traded drugmaker Allos Therapeutics announced Thursday, March 3, it secured $50 million in private equity from Warburg Pincus to help bring its lead cancer medicine to market. The FDA granted tentative approval last year for Efaproxyn, which fights brain metastases of breast cancer by improving the results of brain radiation therapy. But to get full FDA approval, Allos must successfully complete its final, Phase III round of clinical tests, in which 360 women are participating, according to Allos.